Abstract: According to an embodiment, a battery includes an exterior container, a lid member, a plurality of electrode groups, a first lead, a second lead, and an electrode terminal. The lid member closes an opening of an inner cavity of the exterior container, and the plurality of electrode groups are stored in the inner cavity. A first current collecting tab protruding toward the lid member in a first electrode is joined with the first lead, and a second current collecting tab protruding toward the lid member in the second electrode different from the first electrode is joined with the second lead separate from the first lead. The first and second leads are together connected to the electrode terminal exposed on an outer surface of the lid member.

Abstract: A pixel shifting device according to the present disclosure includes a first frame which is configured to hold an optical member, and which oscillates around a first oscillation axis, a second frame which is coupled to the first frame, and which oscillates around the second oscillation axis, a base to be coupled to the second frame, a first actuator for oscillating the first frame, a second actuator which is disposed in an area at a side at which the first actuator is disposed in the second frame, and which oscillates the second frame, and a frame reinforcement member which is disposed in an area at a side at which the first actuator and the second actuator are disposed in the second frame, and which has a first surface having contact with a surface of the second frame.

Abstract: A pixel shifting device includes a first frame which holds an optical member, and which oscillates around a first oscillation axis, a second frame oscillating around a second oscillation axis, a base to be coupled to the second frame via a first coupling part, a pair of first oscillation shaft formation parts for coupling the first frame and the second frame, a first actuator for oscillating the first frame, and a second actuator for oscillating the second frame, wherein the second frame and the base have an extending part which extends along the second oscillation axis, and in which the second actuator is disposed, and the pair of first oscillation shaft formation parts have a pair of second coupling parts for coupling the first and second frames, and a pair of beams extending on the second frame respectively from the pair of second coupling parts along the second oscillation axis.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: An optical device includes an optical member having an optical area on which light incidents, the optical area having a rectangular shape in a plan view, a first actuator configured to displace the optical member around a first axis which passes through the center of the optical area in the plan view, and which forms an angle smaller than 90° with a first side of the optical area, and a second actuator configured to displace the glass plate around a second axis which passes through the center of the optical area, and which is perpendicular to the first axis.

Abstract: A method of driving an optical device is provided. The optical device including an optical member, a first actuator which displaces the optical member around a first axis, and a second actuator which displaces the optical member around a second axis perpendicular to the first axis. The method including exciting the first actuator by inputting a first drive signal to the first actuator, exciting the second actuator by inputting a second drive signal to the second actuator, and setting a value of the second drive signal to a value for substantially stopping exciting the second actuator in a period of the exciting the first actuator.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: A projector according to an aspect of the present disclosure includes a light source apparatus, an image generator, an optical path changer, and a projection optical apparatus. The image generator includes a light modulator that modulates the light emitted from the light source apparatus in accordance with image information to generate the image light, and a first holder that holds the light modulator. The optical path changer includes an optical part that the image light outputted from the image generator enters, an optical support section that pivotably supports the optical part, and a second holder that holds the optical support section. The projection optical apparatus includes a projection system that the light emitted from the optical path changer enters, and a third holder that holds the projection system. The first and second holders are fixed to the third holder.

Abstract: A projector according to an aspect of the present disclosure includes an optical path changer that is provided between an image formation unit and an projection optical unit and changes the optical path of image light from the image formation unit, a linkage frame that links the image formation unit and the projection optical unit to each other, and a vibration absorbing member that absorbs vibration generated by the optical path changer. The optical path changer includes a base member, an optical member, and a swing frame that supports the optical member and is swingably supported relative to the base member. The vibration absorbing member has vibration absorbing surfaces that are in contact with the base member of the optical path changer, and the vibration absorbing surfaces are in contact with support surfaces of the linkage frame to cause the support surfaces to support the optical path changer.

Abstract: An optical device includes an optical device including, a movable frame configured to hold an optical member, and a coupling frame to be coupled to the movable frame via an oscillation axis, and a stationary frame to which the coupling frame is fixed via a vibration absorbing member. The stationary frame has a shaft part to which the vibration absorbing member is attached, and a first surface and a second surface opposed to each other outside the shaft part, the coupling frame is disposed so as to be separated from the shaft part, the first surface, and the second surface with the vibration absorbing member, and a thickness of the vibration absorbing member existing between the coupling frame and the first surface and/or the second surface is thicker than a thickness of the vibration absorbing member existing between the coupling frame and the shaft part of the stationary frame.

Abstract: An air-conditioning system (1) includes an air conditioner (3), a management device (2), and a management server (4). The air conditioner (3) includes an auxiliary storage (33), an authentication information acquirer (300) to acquire authentication information from the management device (2) by sending identification information, which is information for identifying the air conditioner (3), to the management device (2) via a private network, and save the acquired authentication information in the auxiliary storage (33), and an authentication information presenter (301) to present, to the management server(4), the authentication information saved in the auxiliary storage (33), when accessing the management server (4) via a public network.

Abstract: A mist blower in one aspect of the present disclosure includes an air blower, an air feed pipe, a tank, a liquid feed pipe, a nozzle, a first electromagnetic valve, a controller, and a first manual switch. The first electromagnetic valve (i) opens the liquid feed pipe in response to the first electromagnetic valve being activated and (ii) closes the liquid feed pipe in response to the first electromagnetic valve being deactivated. The controller activates or deactivates the air blower and the first electromagnetic valve. The first manual switch (i) is manually moved by a user of the mist blower and (ii) commands the controller to activate or deactivate the air blower based on a movement of the first manual switch.

Abstract: A liquid crystal projector includes a liquid crystal panel configured to generate a modulated image, a sensor configured to detect a temperature of the liquid crystal panel, an optical shift element configured to shift an emission optical path of the modulated image generated by the liquid crystal panel, and a control circuit configured to control a velocity of a shift in the optical shift element according to the temperature detected by the sensor.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: A projector includes an optical path change device placed between a light modulation device and a projection optical device. The optical path change device has an optical member holding part that holds an optical member that a light modulated by the light modulation device enters, and a supporting member that swingably supports the optical member holding part. The supporting member is supported by a holding member that holds the light modulation device or the projection optical device.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: A projector according to an aspect of the present disclosure includes an optical path changer that is provided between an image formation unit and an projection optical unit and changes the optical path of image light from the image formation unit, a linkage frame that links the image formation unit and the projection optical unit to each other, and a vibration absorbing member that absorbs vibration generated by the optical path changer. The optical path changer includes a base member, an optical member, and a swing frame that supports the optical member and is swingably supported relative to the base member. The vibration absorbing member has vibration absorbing surfaces that are in contact with the base member of the optical path changer, and the vibration absorbing surfaces are in contact with support surfaces of the linkage frame to cause the support surfaces to support the optical path changer.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.